Protara Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Protara Therapeutics, Inc. (TARA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 89.71 thousand shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2025-03-05
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2019-12-31 was -2.34M shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2019-09-30 was 1.79M shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2018-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2018-09-30 was 0.00 shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 89.71K shares.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2019 was 63.95K shares, a 52.22% increase from fiscal 2018.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2018 was 42.01K shares, a 58.09% decline from fiscal 2017.
- Protara Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2017 was 100.25K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2024-12-31 | 89.71K shares 10-K · filed 2025-03-05 | |||
| 2019-12-31 | -2.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | -542.72K shares derived: sum of 2 quarters · filed 2020-03-20 | 63.95K shares 10-K · filed 2020-03-20 | |
| 2019-09-30 | 1.79M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | 2.40M shares 10-Q · filed 2019-10-31 | ||
| 2019-06-30 | 606.67K shares 10-Q · filed 2019-08-07 | |||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | 0.00 shares derived: sum of 2 quarters · filed 2019-03-13 | 35.31K shares derived: sum of 3 quarters · filed 2019-03-13 | 42.01K shares 10-K · filed 2019-03-13 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | 35.31K shares derived: sum of 2 quarters · filed 2018-11-07 | 42.01K shares 10-Q · filed 2018-11-07 | 44.85K shares derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-06-30 | 35.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 42.01K shares 10-Q · filed 2018-08-07 | 44.85K shares derived: sum of 3 quarters · filed 2018-08-07 | |
| 2018-03-31 | 6.70K shares 10-Q · filed 2018-05-09 | 9.54K shares derived: sum of 2 quarters · filed 2018-05-09 | ||
| 2017-12-31 | 2.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | 100.25K shares 10-K · filed 2018-03-14 | ||
| 2017-09-30 | 97.41K shares 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |